a(CHEBI:"EC 3.1.1.7 (acetylcholinesterase) inhibitor") increases path(MESH:"Mental Processes")

PubMed:24511233

The current primary treatments for AD symptoms are acetylcholinesterase inhibitors (AChEIs) such as donepezil, tacrine, galantamine, and rivastigmine, which potentiate cholinergic signaling.18,19 These treatments not only provide improvements in cognitive symptoms associated with AD,20,21 but also show efficacy in treating the psychiatric symptoms.

Related Edges 2

• a(CHEBI:"EC 3.1.1.7 (acetylcholinesterase) inhibitor") increases bp(GO:"synaptic transmission, cholinergic")
• a(CHEBI:"EC 3.1.1.7 (acetylcholinesterase) inhibitor") increases bp(GO:cognition)

MeSH

Alzheimer Disease

BEL Commons is developed and maintained in an academic capacity by Charles Tapley Hoyt and Daniel Domingo-Fernández at the Fraunhofer SCAI Department of Bioinformatics with support from the IMI project, AETIONOMY. It is built on top of PyBEL, an open source project. Please feel free to contact us here to give us feedback or report any issues. Also, see our Publishing Notes and Data Protection information.

If you find BEL Commons useful in your work, please consider citing: Hoyt, C. T., Domingo-Fernández, D., & Hofmann-Apitius, M. (2018). BEL Commons: an environment for exploration and analysis of networks encoded in Biological Expression Language. Database, 2018(3), 1–11.